Effects of Citrus aurantium extract, caffeine, and St. John's Wort on body fat loss, lipid levels, and mood states in overweight healthy adults

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 3, 1999, Pages 145-153

  Colker, Carlon M ^a   Kalman, Douglas S ^b   Torina, Georgeann C ^a   Perlis, Theresa ^c   Street, Chris ^d  

^a GREENWICH HOSPITAL   (United States)

^b Clinical Research   (United States)

^c National Development and Research Institutes (NDRI) Inc   (United States)

^d TSI University Laboratories   (United States)

Author keywords

Caffeine; Citrus aurantium; Exercise; Nutrition; Obesity; St. John's Wort; Synephrine; Weight loss

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; CHOLESTEROL; CITRUS FRUIT EXTRACT; HYPERICUM EXTRACT; OXEDRINE; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CALORIC RESTRICTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FATIGUE; HUMAN; HYPERICUM PERFORATUM; KINESIOTHERAPY; LIPID BLOOD LEVEL; MOOD; NUTRITION; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

CITRUS AURANTIUM;

EID: 0032999912     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)88523-9     Document Type: Article

References (23)

1. Hirsch J, Liebel R. The genetics of obesity. Hosp Pract. 1998;3:55-77.
2. Wadden TA, Berkowitz RI, Vogt RA, et al. Lifestyle modification in the pharmacological treatment of obesity: A pilot investigation of a potential primary care approach. Obes Res. 1997;5:218-226.
3. Schwartz MW. Regulation of appetite and body weight. Hosp Pract. 1997;7:109-119.
4. Schaefer DC, Cheskin LJ. Update on obesity treatment. Gastroenterologist. 1998,6:136-145.
5. Daly PA, Krieger DR, Dullo AG, et al. Ephedrine, caffeine and aspirin: Safety and efficacy for treatment of human obesity. Int J Obes. 1993;17(Suppl 1):S73-S78.
6. Spraul M, Ravussin AM, Fontvielle R, et al. Reduced sympathetic nervous system activity - A potential mechanism predisposing to body weight gain. J Clin Invest. 1993;92:1730-1735.
7. Bray GA, Ryan D. Drugs used in the treatment of obesity. Diabetes Rev. 1997;5:83-100.
8. Walston J, Silver K, Bogardus WC, et al. Time of onset of NIDDM and genetic variation in the β-3 adenoreceptor gone. NEJM. 1995;333:343-347.
9. Hoffstedt J, Wahrenberg H, Thorne A, Lonnqvist F. The metabolic syndrome is related to β-3 adenoreceptor sensitivity in visceral adipose tissue. Diabetologia. 1996;39:838-844.
10. Astrup A, Toubro S, Cannon S, et al. Caffeine: A double blind, placebo-controlled study of its thermogenic, metabolic and cardiovascular effects in healthy volunteers. Am J Clin Nutr. 1990;51:759-767.
11. Tendera E. Effect of ephedrine and theophylline on weight loss, resting energy expenditure and lipoprotein lipase activity in obese over-fed rats. Int J Obes. 1993;17:343-347.
12. DiPietro L, Stunkard AJ. Depressive symptoms and weight change in a national cohort of adults. Int J Obes. 1992;16:745-753.
13. Linde K. St. John's Wort for depression: An overview and meta-analysis of randomized clinical trials. BMJ. 1996;313:253-258.
14. Vorbach EU. Effectiveness and tolerance of the hypericum extract LI 160 in comparison to imipramine: Randomized double blind study with 135 outpatients. J Geriatr Psychiatry Neurol. 1994;7(Suppl 1):S19-S24.
15. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. NEJM. 1995;332:621-627.
16. Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes. 1993;17(Suppl 1):S41-S43.
17. Horton TJ, Geissler CA. Post-prandial thermogenesis with ephedrine, caffeine, and aspirin in lean, pre-disposed obese and obese women. Int J Obes. 1996;20:91-97.
18. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures II: Human studies. Int J Obes. 1986;10:467-481.
19. Lake CR, Quirk RS. CNS stimulants and the look-a-like drugs. Psychiatr Clin North Am. 1984;7:689-701.
20. Airriess CN, Rudling JE, Midgley JM, Evans PD. Selective inhibition of adenyl cyclase by octopamine via a human cloned alpha 2A-adrenoreceptor. Br J Pharmacol. 1997;122:191-198.
21. Foreyt JP. An etiologic approach to obesity. Hosp Pract. 1997;8:123-146.
22. Chatterjee SS, Bhattacharya SK, Wonnemann M, et al. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci. 1998;63:499-510.
23. Laakmann G, Schule C, Baghai T, Kieser M. St. John's Wort in mild to moderate depression: The relevance of hyperforin for clinical efficacy. Pharmacopsychiatry. 1998;6(Suppl 1):54-59.